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Background: The reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) is a widely used,
highly sensitive laboratory technique to rapidly and easily detect, identify and quantify gene expression. Reliable
RT-qPCR data necessitates accurate normalization with validated control genes (reference genes) whose expression is
constant in all studied conditions. This stability has to be demonstrated.
We performed a literature search for studies using quantitative or semi-quantitative PCR in the rat spared nerve injury
(SNI) model of neuropathic pain to verify whether any reference genes had previously been validated. We then analyzed
the stability over time of 7 commonly used reference genes in the nervous system – specifically in the spinal cord dorsal
horn and the dorsal root ganglion (DRG). These were: Actin beta (Actb), Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), ribosomal proteins 18S (18S), L13a (RPL13a) and L29 (RPL29), hypoxanthine phosphoribosyltransferase 1
(HPRT1) and hydroxymethylbilane synthase (HMBS). We compared the candidate genes and established a stability
ranking using the geNorm algorithm. Finally, we assessed the number of reference genes necessary for accurate
normalization in this neuropathic pain model.
Results: We found GAPDH, HMBS, Actb, HPRT1 and 18S cited as reference genes in literature on studies using the SNI
model. Only HPRT1 and 18S had been once previously demonstrated as stable in RT-qPCR arrays. All the genes tested in
this study, using the geNorm algorithm, presented gene stability values (M-value) acceptable enough for them to qualify
as potential reference genes in both DRG and spinal cord. Using the coefficient of variation, 18S failed the 50% cut-off
with a value of 61% in the DRG. The two most stable genes in the dorsal horn were RPL29 and RPL13a; in the DRG they
were HPRT1 and Actb. Using a 0.15 cut-off for pairwise variations we found that any pair of stable reference gene was
sufficient for the normalization process.
Conclusions: In the rat SNI model, we validated and ranked Actb, RPL29, RPL13a, HMBS, GAPDH, HPRT1 and 18S as
good reference genes in the spinal cord. In the DRG, 18S did not fulfill stability criteria. The combination of any two
stable reference genes was sufficient to provide an accurate normalization.
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While 20%-30% of the general populace are affected by
chronic pain, a significant proportion, about 7%, experi-
ences neuropathic pain characteristics [1,2]. Defined by
the International Association for the Study of Pain (IASP)
as a pain “caused by a lesion or disease of the somatosen-
sory nervous system”, neuropathic pain represents a daily
challenge to medical practice and a worldwide public
health problem since it is often refractory to treatment.
Several animal models of neuropathic pain are used to
study its different pathophysiological mechanisms and
hopefully uncover new targets for treatment. Among
them, the spared nerve injury (SNI) model [3] represents
an easy-to-perform and robust model of peripheral nerve
injury. The axotomy of the tibial and peroneal branches
of the sciatic nerve, sparing the sural nerve, allows a
straightforward testing of the hind paw’s sural nerve ter-
ritory for signs of hyperalgesia. After a peripheral nerve
injury in rodents, numerous alterations in the somato-
sensory nervous system can be observed, which together
lead to a hyperexcitability of the system [4]. Besides
changes affecting the primary nociceptors whose cell
bodies are in the dorsal root ganglion (DRG) or the sec-
ondary neurons in the dorsal horn projecting into the
brain, glial cells also react dramatically to a peripheral
nerve injury like SNI. A common approach used to eluci-
date such changes in molecular machinery is to explore
modifications in the expression of relevant genes [5,6].
These variations can be detected and quantified in a sensi-
tive, specific way using a reverse transcription quantitative
real-time polymerase chain reaction (RT-qPCR), assuming
that an accurate normalization has been performed with
reference genes that have proved stable in all biological
replicates and experimental conditions [7-10]. The recently
published guidelines on the “minimum information for
publication of quantitative real-time PCR experiments”
(MIQE) strongly recommended the validation of reference
genes used in different cell types and conditions [7]. These
guidelines outline the importance of RT-qPCR accuracy
and recommend following detailed procedures to produce
the most robust and reproducible RT-qPCR data.
Algorithms like geNorm or NormFinder were devel-
oped to help researchers assess candidate reference
genes. GeNorm has been well described [9] and widely
accepted as a very useful tool for the normalization of
RT-qPCR data [11]. It measures the stability of potential
reference genes by comparing their expression levels
against one another. The expression ratio is supposed to
be the same in all biological and technical replicates.
This pairwise comparison permits the assessment and
ranking of candidate reference genes and additionally
demonstrates how many are necessary for an accurate
normalization [9,11]. To our knowledge, a validation of
reference genes for the rat after spared nerve injury hadnever been published. We therefore performed a litera-
ture search for all studies using quantitative or semi-
quantitative PCR in the SNI model and listed all the
reference genes used. We then tested a total of 7 genes –
including commonly used reference genes in the nervous
system and those used in the SNI model – at differ-
ent time points after nerve lesion in the spinal cord
dorsal horn and in the DRG. These genes were Actin
beta (Actb), Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), ribosomal proteins 18S (18S), L13a (RPL13a)
and L29 (RPL29), hypoxanthine phosphoribosyltransferase
1 (HPRT1) and hydroxymethylbilane synthase (HMBS)
[12-15]. Selected genes were related to various meta-
bolic pathways to avoid any co-regulation [9].
Methods
Animals
We carried out our experiments on Sprague–Dawley rats
(Charles River, L’Abresle, France) weighing 250–300 grams.
They were housed under 12 h day/night photoperiodic
conditions, at a constant temperature and with free access
to water and food. All procedures were approved by the
Canton of Vaud’s Animal Experimentation Committee and
were in accordance with the Swiss Federal Law on Animal
Welfare and the IASP’s guidelines [16].
Surgery
Rats were anesthetized with isoflurane 1.5%-2.5% (Abott,
Baar, Switzerland) and surgical procedures were performed
as previously described [3,17]. Briefly, the left sciatic nerve
was exposed at the mid-thigh level distal to the trifurca-
tion, tibial and common peroneal branches were tightly
ligated with 5.0 silk and axotomized, leaving the sural
branch intact. Muscle and skin were closed in two layers
and animals were allowed to recover. Three rats were
sacrificed at 2, 4, 7, 10, 14 and 21 days after surgery.
Literature search
We performed a literature search in the PubMed database
using the keywords “spared nerve injury” and selected
every study using semi-quantitative PCR or RT-qPCR in
the rat SNI model (13 April 2013). We only selected arti-
cles in English. Reference genes used were noted, as were
indications of their validation in the models.
RNA isolation and reverse transcription
Animals were transcardially perfused with NaCl 0.9% in
order to expel the blood from collected tissue. Ipsilateral
L4 and L5 DRG and spinal cord dorsal horn were rapidly
dissected and immediately stored in RNAlater® (Qiagen,
Switzerland) for stabilization at 4°C overnight, and then
frozen at −80°C until processed. Samples were first
homogenized with a POLYTRON® homogenizer and
then total RNA was extracted using the RNeasy Plus
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gDNA, we treated the dorsal horn samples with a
DNase (RNAqueous®-4PCR Kit, Ambion) and then the
inactivation reagent recommended in the manufac-
turer’s instructions.
Nucleic acid purity was assessed measuring the
A260/A280 ratio by spectrophotometer (NanoDrop).
Total RNA integrity (RIN) and quantity were deter-
mined with an Agilent 2100 Bioanalyser (Agilent
Technologies). RNA used had to have both a A260/
A280 ratio between 1.8 and 2.1, as well as a RIN ≥8
for dorsal horn RNA extractions and ≥6.9 for DRG
samples. The reverse transcription was achieved using
Omniscript RT Kit (Qiagen), according to manufac-
turer’s instructions. All reactions took place for 1h at
37°C in a final volume of 40 μl containing 1 μg total
RNA in the presence of 20 units RNase inhibitor
(RNasin® Ribonuclease Inhibitor, Promega), 1 μg ran-
dom hexamers (Microsynth), 4 μl 10× Buffer RT, 0.5
mM dNTPs and 8 units Omniscript reverse tran-
scriptase (Omniscript RT Kit, Qiagen).Table 1 Specification of used reference genes
Gene symbol Sequence (5'->3')
Full name
Accession number
18S Fw: GGCTCATTAAATCAGTTATGGT
18S ribosomal RNA Rev: GTTGGTTTTGATCTGATAAATG
V01270
RPL29 Fw: ACAGAAATGGCATCAAGAAA
Ribosomal protein L29 Rev: TCTTGTTGTGCTTCTTGGCAA
NM_017150
RPL13a Fw: TCTCCGAAAGCGGATGAACA
Ribosomal protein L13A Rev: CAACACCTTGAGGCGTTCCA
NM_173340
Actb Fw: GGAGATTACTGCCCTGGCTCC
Actin, beta Rev: GACTCATCGTACTCCTGCTTG
NM_031144
HPRT1 Fw: GCATCTAAGAGGTTTCCCCAG
Hypoxanthine phosphoribosyl-transferase 1 Rev: GCATTTAAAAGGAACGGTTG
NM_012583
HMBS Fw: GAGACCATGCAGGCCACCAT
Hydroxymethyl-bilane synthase Rev: TTGGAATGTTCCGGGCAGTG
NM_013168
GAPDH Fw: CCCCCAATGTATCCGTTGTG
Glyceraldehyde-3-phosphate Rev: TAGCCCAGGATGCCCTTTAG
dehydrogenase
NM_017008
Fw forward, Rev reverse primer sequence, DH dorsal horn, DRG dorsal root ganglion
1 from our laboratory database.Selection of reference genes and primer design
Reference genes were chosen from those used previ-
ously in the SNI model. Other potentially suitable ref-
erence genes were selected among those used in
published literature on the nervous system (Table 1).
Whenever possible, primers fulfilled the following
recommended criteria: amplicon length of 60 bp-150
bp, location of primers on two different exons, primer
sequence length of 18 bp-25 bp, melting temperature
of 60°C +/−1°C and GC content of 40%-60%
[7,18-20]. Primer specificity was checked in silico
(Primer-BLAST Tool from http://www.ncbi.nlm.nih.
gov/tools/primer-blast/) [21]. All oligonucleotides
were supplied unmodified and desalted (Microsynth
AG, Switzerland).
Quantitative real-time PCR (qPCR)
We performed qPCR on an iQ5 Cycler (Bio-Rad)
with SYBR Green I. The reactions were carried out
in 96-well plates (Thermo-Fast® 96 Semi-Skirted PCR
Plate, Thermo Scientific, Switzerland) each with aPosition Product
length
Intron
inclusion
RTqPCR efficiency
in DH/DRG
Ref.
TCCT 94-119 147 no 78%/70% [22]
CACG 240-215
CCC 96-118 105 yes 81%/77% [15]
A 200-179
C 185-205 145 yes 88%/73% [14]
329-310
TA 1023-1045 150 yes 85%/63% [14]
CTG 1172-1149
T 1133-1154 76 no 70%/74% 1
AC 1208-1187
1007-1026 97 yes 78%/72% [15]
1084-1103
780-799 118 yes 89%/87% [23]
T 877-897
.
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100-fold dilution of cDNA, 10 μl of iQ™ Sybr® Green
Supermix (2× qPCR mix contains dNTPs, 50 U/ml
iTaq DNA polymerase, 6 mM MgCl2, SYBR Green I,
enhancers, stabilizers, 20 nM fluorescein) (Bio-Rad,
Switzerland), 2 μl of each primer 1–3 μM and 1 μl
water. We optimized qPCR conditions on the iQ5
thermal gradient cycler and by testing different con-
centrations of primers and templates. The qPCR pro-
gram began with an initial three-minute denaturation
step at 95°C to activate the hot-start iTaq™ DNA polymer-
ase. This was followed by 45 cycles of 10 s at 95°C
for denaturation and 45 s at 60°C for annealing and
extension.
We confirmed the amplification of specific qPCR
products by performing a melting-curve step at the
end of each run. Serial dilution curves for each primer
allowed us to calculate qPCR efficiencies. The 100-
fold diluted cDNA utilized for all the amplifications
was within the linear dynamic range of the calibration
curve – between 10 and 1000-fold dilution. Across
all the assays, none of the quantification cycle (Cq)
values was higher than 30. No-template and no-
reverse transcription controls were run to determine
any contamination or the generation of primer di-
mers. All amplifications were run in triplicate, and
any doubtful curves were excluded. To minimize
technical variation between samples through differ-
ent runs we preferred the sample maximization
method [11], i.e. a run contained all the samples for
one gene of interest respective to one reference
gene.
Data analysis
Raw data was collected and computed by iQ5 BioRad
software with an automated analysis of the baseline and
threshold of each run, and then exported in Excel files
for further analyses. We rescaled all Cq values for each
gene to the lowest Cq value as an internal control,
converted these rescaled Cq logarithmically into linear,
relative quantities taking into account the gene specific
amplification efficiency [relative quantity = (1+efficiency) ^
(Cqinternal control-Cqsample)]. Finally, we calculated arithmet-
ical means from the replicates [11,24]. To explore the sta-
bility of each candidate gene we calculated M-values from
the geNorm algorithm and coefficients of variation (CV)
[9,11]. The M-value corresponds to the average pairwise
variation between a gene and the other candidate genes.
The more this value tends to zero, the more stably the
gene is expressed in comparison to the others. For a het-
erogeneous sample, a candidate gene with an M-value
below 1 can be considered as a reliable reference gene
[11]. The CV for a gene was obtained by calculating the ra-
tio of the standard deviation (σ) to the mean (μ) of relativequantities (CV = σ / μ). For a heterogeneous panel, a value
below 50% is proposed as satisfactory [11].
To rank the genes that satisfied the above criteria,
M-values were recalculated after stepwise elimination
of the worst candidate. To assess the number of refer-
ence genes needed for an accurate normalization, the
effect of inclusion of a supplementary gene to those
already considered stable was determined by calculat-
ing the pairwise variation of the added candidate
gene to the others (standard deviation of logarithmic-
ally transformed expression ratios). If this pairwise
variation goes below 0.15, no supplementary gene is
needed [9].
Results
Reference genes used in the SNI model
We found 484 articles in the PubMed database using
“spared nerve injury” as keywords. Twenty-six arti-
cles were retrieved with semi-quantitative PCR or
RT-qPCR performed in the rat DRG, spinal cord or
brain. Despite its rigorous validation never having
been mentioned, GAPDH was the most commonly
used reference gene (16 times) whether in the DRG
or in the dorsal horn. This was followed by Actb
and 18S (3 times), HPRT1 (twice) and HMBS (once).
HPRT1 and 18S were the only two reference genes
with validation in the rat SNI model (Table 2).
Validation of reference genes in spinal cord dorsal horn
over time after SNI
Rat spinal cord dorsal horn samples were analyzed
in an overall panel without differentiating any
timepoints, i.e. throughout a temporal follow-up with
naive animals, 2nd, 4th, 7th, 10th, 14th and 21st
postoperative day animals. The pairwise comparison
of all the potential reference genes (Actb, 18S,
GAPDH, RPL13a, RPL29, HPRT1 and HMBS) calcu-
lated using geNorm resulted in M-values below 0.5
for all but the 18S gene, which showed 0.52 (Figure 1). All
genes were below the M-value cut-off of 1.0 pro-
posed for a heterogeneous panel. CV ranged from
20% for HMBS to 34% for GAPDH and RPL13a, i.e.
below the 50% cut-off for stability in a heterogeneous
panel.
Validation of reference genes in DRG after SNI in a
time-dependent panel
As for the dorsal horn, DRG samples were analyzed in
an overall panel without differentiating any timepoints.
M-values were below 1.0 and CV below 50% for Actb,
GAPDH, RPL13a, RPL29, HPRT1 and HMBS. The 18S
reference gene had the worst M-value, at 0.8, but this
was still acceptable within the selection. However, we
Table 2 List of reference genes in the rat spared nerve injury model
Article PCR method Sample Reference genes Validation
Kanda et al., 2013 [25] PCR L4/L5 SC GAPDH no
Zhou et al., 2013 [26] RT-qPCR L4/L5 DRG GAPDH no
Kashimoto et al., 2013 [27] RT-qPCR L4/L5 SC GAPDH no
Shankarappa et al., 2012 [28] RT2 Profiler PCR array L4/L5 DRG HPRT1 validated1
Inquimbert et al., 2012 [29] PCR L4/L5 DH GAPDH no
Zapata et al., 2012 [30] RT-qPCR RVM 18S and HMBS no
Samad et al., 2013 [31] PCR L4 DRG GAPDH no
Kobayashi et al., 2012 [32] RT-qPCR L4/L5 SC GAPDH no
Liu et al., 2012 [33] RT-qPCR L4–L6 SC Actb no
Tochiki et al., 2012 [34] PCR L4-L6 DH HPRT1 no
Okubo et al., 2012 [35] RT-qPCR L4-L5 SC GAPDH no
Del Rey et al., 2011 [36] PCR hippocampus not mentioned no
Kühlein et al., 2011 [37] RT-qPCR and PCR DH and DRG Actb and 18S no
Yamanaka et al., 2011 [38] RT-qPCR L4, 5 DRG GAPDH no
de Novellis et al., 2011 [39] RT-qPCR mPFC Actb no
Vega-Avelaira et al., 2009 [40] PCR L4/L5 DRG GAPDH no
Costigan et al., 2009 [41] PCR L4/L5 DH GAPDH no
Okubo et al., 2010 [42] RT-qPCR L4-L5 SC GAPDH no
Staaf et al., 2009 [43] Taqman Low Density Arrays L4 DRG 18S validated2
Moss et al., 2008 [44] PCR L4/5 DRG GAPDH no
Berta et al., 2008 [45] PCR L4 and L5 DRGs GAPDH no
Millecamps et al., 2007 [46] PCR mPFC GAPDH no
Moss et al., 2007 [47] PCR L4/L5 dorsal horn GAPDH no
Apkarian et al., 2006 [48] RT-qPCR brainstem, thalamus, and prefrontal cortex GAPDH no
Pertin et al., 2005 [49] PCR L4/L5 DRG GAPDH no
Takahashi et al., 2003 [50] RT-qPCR L5 DRG GAPDH no
Literature search in the PubMed database of studies using semi-quantitative PCR or RT-qPCR in the rat SNI model.
PCR semi-quantitative polymerase chain reaction, RT-qPCR reverse transcription quantitative real-time polymerase chain reaction, SC spinal cord, DRG dorsal root
ganglion, DH dorsal horn, RVM rostral ventromedial medulla, PL-IL prelimbic and infralimbic, mPFC medial prefrontal cortex.
1 HPRT1 validated among 5 reference genes.
2 See Discussion.
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(Figure 1).
Ranking of reference genes
We reanalyzed the 7 tested reference genes (Actb,
GAPDH, RPL13a, RPL29, HPRT1, HMBS and 18S) to
rank them. After each step, the gene with the highest
M-value was eliminated until we obtained the two
most stable genes from the list. No further discrimin-
ation was possible.
In the spinal cord dorsal horn, the 2 most stable genes
remaining after the stepwise elimination were RPL29
and RPL13a, and then in increasing order GAPDH,
Actb, HMBS, HPRT1 and 18S (Figure 2A).
In the DRG, the 2 most stable genes remaining after
the stepwise elimination were HPRT1 and Actb, andthen in increasing order RPL29, RPL13a, HMBS,
GAPDH and 18S (Figure 2B). The latter is used because
this ranking only takes into account the M-value and
not the CV.
Minimal number of reference genes
In the dorsal horn samples, the calculation of pair-
wise variations resulted in values much lower than
0.15 along the entire time course and in all samples.
Using the two best reference genes the pairwise vari-
ation in dorsal horn was 0.07 (Figure 3). The addition
of a supplementary reference gene did not signifi-
cantly lower the pairwise variation. Results for DRG
were similar, with a low pairwise variation of 0.05 if
only the two most stable reference genes were taken
in consideration.
Figure 1 Analysis of reference gene stability. Assessment of reference gene stability, in the ipsilateral dorsal horn (A) and L4-L5 dorsal root
ganglia (B) in the rat spared nerve injury model using M-value (left) from the geNorm algorithm and coefficient of variation (CV) (right).
Candidate genes are classified from left to right by increasing order of M-value, from most to least stable. The cut-off for stability is 1 for M-value
and 50% for CV (dotted line).
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reference genes on our list for dorsal horn and DRG,
and their pairwise variation was still below 0.15.
Discussion
Here, we tested the stability of seven candidate refer-
ence genes according to the geNorm algorithm toFigure 2 Ranking of reference genes. Stepwise calculation of stability by
M-values in the spinal cord dorsal horn (A) and the dorsal root ganglia (B)ensure accurate RT-qPCR normalization. M-values
below 1.0 together with CV lower than 50% for
Actb, GAPDH, RPL13a, RPL29, HPRT1, and HMBS
identified these candidate genes as good controls in
the rat SNI model in the spinal cord dorsal horn
and DRG. The 18S gene could not be validated in
DRG because of a CV above 50%.excluding the least stable gene and averaging the remaining
. Insert: list of reference genes ranked from the most to least stable.
Figure 3 Determination of the optimal number of control genes for accurate normalization. Determination of the number of reference
genes to consider for an accurate normalization in spinal cord dorsal horn (A) and dorsal root ganglia (B) by calculating pairwise variation (V)
after stepwise elimination of the worst reference gene.
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be enormous compared to the baseline and also over
time [51]. Because of this heterogeneity, meticulous RT-
qPCR procedures relying on MIQE recommendations
are essential to obtain consistent data. The most frequently
chosen reference gene for RT-qPCR normalization after
SNI in the rat is GAPDH, but its expression level had, to
our knowledge, never been confirmed as being stable in
this model (Table 2). Here, we confirm that GAPDH is
a good candidate gene, even if it is not the most stable
in our series.
The only 2 reference genes with previously mentioned
validation in the rat SNI model are HPRT1 and 18S.
HPRT1 was used by Shankarappa et al. in DRG [28] at 2
timepoints after injury and chosen from among 5 differ-
ent reference genes on an array. After showing that 18S
had a very low variation of Cq values in all data sets,
from both SNI and naive groups, Staaf et al. used it to
normalize and compare the expression of the transient
receptor potential (TRP) family of genes in DRG after
SNI. They mentioned neither ranking between the differ-
ent reference genes, nor the criteria used to choose 18S
from among their list of them [43]. These demonstra-
tions are part of the workflow of RT-qPCR arrays where
several reference genes are proposed, and their analysis
is usually fully integrated in the procedure.
GeNorm is a popular algorithm for assessing different
reference genes from a given panel [9,11]. The calcula-
tion of M-values permits measurement of an average
variation in the expression ratios of one potential ref-
erence gene with the others and consequently in-
forms us whether the tested gene is constantly expressedcompared to them. The CV of relative quantities of a gene
merely reflects the dispersion of its expression level. It has
been previously demonstrated that a CV below 25% was
typically observed in stable reference genes as long as the
experimental conditions were homogeneous. In a hetero-
geneous panel, such as in the present study, a CV below
50% is acceptable [11]. As it measures the gene-specific
variation, the CV in assessing the stability of a reference
gene assumes a standardization of the procedures for all
samples. Taken together, M-values and the CV are very
useful tools for determining the most accurate reference
genes because the information that they convey is different.
All our candidate genes satisfied an M-value cut-off below
1.0 for a heterogeneous panel. 18S, despite its acceptable
M-value, failed to satisfy the CV cut-off in DRG. Consider-
ing these results 18S could not be validated as a stable ref-
erence gene.
The more the M-value tends to zero, the more the
candidate gene is stable compared to the other tested
genes. Hence the stability of the different genes can be
ranked. A first approximate classification was established
after analyzing all the samples together (Figure 1). Actb,
RPL13a and RPL29 were the 3 best genes in both tis-
sues. A potentially more accurate classification can
be performed if M-values are recalculated in a series of
steps, after elimination of the worst scoring gene at each
step. At the end, the two most reliable reference genes re-
main, but they cannot be further discriminated by defin-
ition of the M-value (Figure 2). Interestingly the ranking
differed between dorsal horn and DRG. We again found
RPL 29 and RPL13a to be the most stable genes in the
spinal cord dorsal horn, however, in the DRG, HPRT1 and
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RPL29. In the present study, differences in the ranking
were very slight, and the former “rough” method would
have been sufficient. In other circumstances, or with an-
other panel of candidate genes, it could be useful to com-
pare them further until a definitive ranking is obtained, so
as to choose only the best control genes from amongst the
candidates. M-value calculations and subsequent ranking
were also performed independently for each different time
point (data not shown) without being able to identify any
time-dependent regulation. The primary goal of this study
was to validate some suitable RT-qPCR reference genes at
different time points, in different tissues, in a widely used
neuropathic pain model.
According to MIQE guidelines, the use of a single
reference gene is not enough to compensate for the
intrinsic variation within that reference gene and
normalization against several reference genes should
be performed [7,9]. To define the minimal number of
necessary reference genes, the pairwise variation per-
mits an assessment of whether the removal of the
worst reference gene may result in a greater variation
(Figure 3). Here, in both DRG and dorsal horn, the
two best candidate genes were sufficient to ensure an
accurate normalization. This demonstration allows us
to state that in our model, using only the two best
reference genes would be sufficient: namely RPL 29
and RPL13a in the spinal cord dorsal horn and
HPRT1 and Actb in the DRG. However, even the
worst pair satisfied stability criteria, with a pairwise
variation less than 0.15. In fact, all pairs of validated
reference genes (not 18S because of its CV above
50%) provided a robust validation in both tissues and at all
time points. GAPDH is often used, but according to MIQE
guidelines it should not be used alone.
The criterion for choosing a reference gene is more
than just its stability. 18S, for example, is disputed as a
reference gene by some authors who argue that it by far
exceeds the mRNA quantity of most genes of interest
and it might be absent from pure mRNA extracts [9].
Conclusions
We validated 7 reference genes in the spinal cord dorsal
horn: (Actin beta (Actb), Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH), ribosomal proteins L13a (RPL13a)
and L29 (RPL29), hypoxanthine phosphoribosyltransferase
1 (HPRT1), hydroxymethylbilane synthase (HMBS) and
18S. In DRG, 18S did not fulfill all our criteria and could
not be retained as a good reference gene, although the
other 6 were. We were able to show that in both tissues,
using any two of the proposed stable reference genes is suf-
ficient to ensure an accurate validation. We were also able
to confirm the stability of GAPDH, which is the most
commonly used reference gene in the SNI model,but it should be used in combination with another
control gene.
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